Bio Tech investor Eco Quest Limited
(ASX:ECQ) says its strategic partner, stem cell company Cynata, has received positive results from a stem cell concept study.
The study relates to the therapeutic treatment of Critical Limb Ischemia, a diabetes related poor blood supply condition.
Ecoquest says therapeutics derived from Cynata’s globally exclusive licensed cellular platform, known as Mesenchymoangioblast’s (MCA), possess great utility in the treatment of damaged vasculature.
Animal testing incorporating MCA’s have produced a number of important results, demonstrating the potential effectiveness of the cellular therapeutics platform.
Cynata CEO Dr Allen Bolands says MCA’s have the potential to make massive quantities of pharmaceutical grade cells in a cost effective manner.
Eco Quest reported a $1.54 million loss in the 2012 financial year.
